HUTCHMED Launches Worldwide Clinical Trials for HMPL-A251 in Solid Tumor Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: aastocks
Clinical Development Announcement: HUTCHMED has initiated a global Phase I clinical development program for HMPL-A251, a novel PI3K/PIKK-HER2 Antibody-Targeted Therapy Conjugate.
Study Details: The first patient received the treatment in China, with the study evaluating HMPL-A251 monotherapy in adults with advanced or metastatic HER2-expressing solid tumors across sites in the US and China.
Analyst Views on 00013
Wall Street analysts forecast 00013 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00013 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 23.420
Low
Averages
High
Current: 23.420
Low
Averages
High
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
